UNSPSC 51422426: Hydrocortisone buteprate

This classification denotes a therapeutic glucocorticoid with the molecular formula C28H40O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O6550D6K3A. The term hydrocortisone buteprate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule hydrocortisone buteprate under HS 29372100. SMILES: CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)COC(=O)CC.

UNSPSC 51422426 Hydrocortisone buteprate is a Commodity code that sits at the bottom of the pharmaceutical products taxonomy, but the recent state and local opportunities posted under this code show little substantive alignment with the code's nominal scope. The two most recent postings — one from Seminole County, Florida soliciting naloxone and drug deactivation systems, and one from the Texas Health and Human Services Commission requesting information on direct-to-manufacturer prescription programs — address pharmaceutical procurement and pharmacy benefit management broadly rather than hydrocortisone buteprate specifically. State and local health agencies, counties, and HHS departments appear to use this code as a catch-all for pharmaceutical procurement and supply chain activities when more granular commodity codes do not fit their immediate needs, a common pattern in state procurement systems where taxonomy precision varies by jurisdiction and legacy coding practices persist.

Recent activity under the code reflects health-department and state-agency procurement in Florida and Texas, with the Seminole County IFB (IFB60459723LAS, due July 26, 2023) representing operational purchasing of emergency-response pharmaceuticals through standard competitive bidding, and the Texas HHS RFI (HHS0017013, posted April 3, 2026) representing exploratory market research into pharmacy benefit program restructuring. The code shows minimal geographic concentration across only two states in the recent record, with no repeat issuing bodies or patterns suggesting sustained procurement activity under the hydrocortisone buteprate code itself. Vendors pursuing state and local work in pharmaceutical procurement should treat this code as a low-signal category — monitor activity under it for jurisdictional outliers, but expect that true opportunities for hydrocortisone buteprate will be rare and that most postings tagged to this code will address broader pharmaceutical or pharmacy-benefit work better matched to adjacent family or class codes in the UNSPSC hierarchy.